Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetoclax treatment can be guided by minimal residual dise...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Blood Adv
Main Authors: Kater, Arnon P., Kersting, Sabina, van Norden, Yvette, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H., Evers, Ludo M., Croon-de Boer, Fransien, Schreurs, John, van der Spek, Ellen, Visser, Hein, Idink, Cecile, Wittebol, Shulamiet, Hoogendoorn, Mels, Tonino, Sanne H., Mobasher, Mehrdad, Levin, Mark-David
Formáid: Artigo
Teanga:Inglês
Foilsithe: American Society of Hematology 2018
Ábhair:
Clinical Trials and Observations
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306887/
https://ncbi.nlm.nih.gov/pubmed/30552161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019422
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla